Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on REX BIONICS PLC. We currently have 9 research reports from 3 professional analysts.
|18Nov16 07:00||RNS||Presentation of REX Case Report at SCI Conference|
|07Nov16 09:47||RNS||Positive Update from Rapper II Clinical Trial|
|24Oct16 07:00||RNS||Stroke & Brain Injury Clinical Trial in Australia|
|27Sep16 01:00||RNS||Directors Interests|
|27Sep16 12:57||RNS||Results of Annual General Meeting|
|19Sep16 10:57||RNS||Retirement of Director|
|01Sep16 05:42||RNS||Posting of Annual Report and Accounts|
Frequency of research reports
Research reports on
REX BIONICS PLC
REX BIONICS PLC
25 Oct 16
"London’s blue chip index is called some 15 points higher during this morning’s opening trade, which should see the FTSE-100 test the psychologically important 7000 level once again. The US markets, whose principal indices all closed higher overnight, remain Europe’s main influence as investors track the territory’s latest round of deals and earnings. While broadly pleasing investors, technology issues continue to lead the way which resulted in the NASDAQ registering a full 1% rise on good trading volumes. Against this background, the Federal Reserve Bank of Chicago President, Charles Evans, delivered a speech in which he predicted three US interest-rate rises before the end of 2017, while effectively suggesting that the central bank should allow its inflation target to be overshot before responding with confidence strangling hikes. Generally, however, his forecasts are not far from the current consensus, although he refused to be drawn of the timing of the first move which the markets continue to anticipate in the form of a 25bp move being delivered before the 2016 year-end. By comparison, Asia ended mixed, with the Shanghai Composite finishing unchanged as a weaker Yuan was countered by gains in resource stocks; the latter also boosted the ASX’s commodity-heavy index while a weaker Yen resulted in the Nikkei closing the session with the region’s strongest gain. No major UK macro data are due for release today, which means that traders will eyes will remain focussed on the US disclosure of consumer confidence and housing figures due this afternoon, with neither the ECB President Mario Draghi’s scheduled lecture or the Bank of England Governor, Mark Carney’s appearance before the Lord’s Committee, expected to provide significant new market-sensitive information. Earnings or trading updates are expected from Anglo American Carpetright (AAL.L), GKN (GKN.L), National Express (NEX.L) and Whitbread (WTB.L). Significant quarterly earnings also due from US majors due this afternoon include Apple and General Motors. " - Barry Gibb, Research Analyst
30 Aug 16
CONCURRENT TECHNOLOGIES (CNC LN) | ELLERSTON GLOBAL INVESTMENTS (EGI AU) | ITM POWER (ITM LN) | LXB RETAIL PROPERTIES PLC (LXB LN) | OSIRIUM TECHNOLOGIES PLC (OSI LN) | P2P GLOBAL INVESTMENTS PLC (P2P LN) | PETRO MATAD LTD (MATD LN) | REX BIONICS PLC (RXB LN) | SAN LEON ENERGY PLC (SLE LN) | SOUND ENERGY PLC (SOU LN)
26 Aug 16
CONCURRENT TECHNOLOGIES (CNC LN) | ITM POWER (ITM LN) | LXB RETAIL PROPERTIES PLC (LXB LN) | OSIRIUM TECHNOLOGIES PLC (OSI LN) | P2P GLOBAL INVESTMENTS PLC (P2P LN) | PETRO MATAD LTD (MATD LN) | REX BIONICS PLC (RXB LN) | SAN LEON ENERGY PLC (SLE LN) | SOUND ENERGY PLC (SOU LN)
30 Nov 16
Abzena (ABZA): Interim results indicate happy customers (BUY) | Horizonte Minerals* (HZM): Fund raise completed (CORP) | SacOil* (SAC): Half-year trading statement (CORP) | Revolution Bars (RBG): New openings (BUY) | Amino Technologies* (AMO): Multi operator FUSION roll out (CORP)
N+1 Singer - Morning Song 30-11-2016
30 Nov 16
Sanderson has delivered full year results in line with expectations and the 19 October trading update after a strong finish to the year compensated for a slower start. A healthy level of pre-contracted recurring revenue (50%), incremental sales to existing customers and new customer wins at higher average order values helped deliver solid revenue growth in both the Digital Retail (+9%) and Enterprise (+12%) divisions. A decent order book and good sales momentum suggest that the company is on track to deliver on unchanged profit expectations for the current year. We continue to view the valuation (FY17 EV/EBITDA 8.6x) as undemanding given an attractive combination of accelerating growth potential, strong cash generation and growing dividends.
N+1 Singer - Morning Song 29-11-2016
29 Nov 16
Vp has reported another impressive set of interims, confirming strong growth in most markets and a positive outlook. Recent acquisitions are bedding in well and the full year outturn is set to exceed previous expectations (5%/6% EPS upgrades in FY17/FY18). The recent Capital Markets Day provided a reminder of Vp’s qualities (specialist focus, high returns, strong cash generation) and its growth potential, which in our view are not reflected in a modest <11x P/E rating. We firmly believe the shares are due a re-rating and see intrinsic value in excess of 800p.
Food intolerance driving growth
29 Nov 16
Omega Diagnostics Group has an established core business providing high quality in vitro diagnostic tests within three core areas of competence – Food Intolerance, Allergy & Autoimmune, Infectious Disease – that are sold in over 100 countries. The group offers steady low single-digit growth which is profitable and cash generative. Investment in new products has seen the launch of a new panel of automated allergy tests and progress on Visitect CD4 for monitoring of HIV positive patients. Interim results highlighted the opportunities to accelerate growth of the business, particularly Allersys, which has drawn attention from its partner.
Small Cap Breakfast
29 Nov 16
Asia Pacific Investment Partner - the research-driven emerging and frontier markets real estate development business intends to float on AIM and conduct a placing in December RM Secured Direct Lending - The secured direct lending fund intends to float on the Main Market on 15 December raising up to £100m Diversified Oil & Gas— Schedule One now out. $60m to be raised. Expected admission 6 December. Creo Medical Group —UK based medical device company focused on surgical endoscopy, a recent development in minimally invasive surgery. Admission due 7 December. Fundraising details TBA.
Continuing to execute strategy on core focus
03 Oct 16
Q216 results were in line with the upper end of company guidance, with sales of €3.4m and an EBITDA loss of €1.4m. aap Implantate continues to focus on its strategic transition to being a pure trauma company, following the recent sale of its Biomaterials business. As the company continues to drive sales of LOQTEQ in Western Europe and the US alongside the implementation of cost reduction measures, we could see a return to sustained growth.